

## Alzinova appoints new Chief Financial Officer

**Alzinova has appointed Håkan Skogström as new Chief Financial Officer ("CFO"), thereby strengthening the management body as a key step in the Company's development**

Håkan Skogström has more than 30 years of experience within economy and finance. His previous positions include CFO/Finance Manager at Laurin Maritime AB and Safe at Sea AB. Johanna Hultgren, the former Finance Manager/CFO at Alzinova AB, will continue to serve on a consultancy basis and remains in the Company. The Company thereby strengthen the finance and economy area. Håkan will take up appointment as CFO today on 5 March 2020.

"I am pleased that we have recruited Håkan Skogström to fill this important role; this is a further step in Alzinovas growth, where we continuously aim to strengthen and develop the organization. This reinforcement brings us closer towards entering the clinical phase," says Kristina Torfgård, CEO.

### For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

### Certified Adviser:

Corpura Fondkommission AB

E-mail: [ca@corpura.se](mailto:ca@corpura.se)

Telephone: 0768-532822

Website: [www.corpura.se](http://www.corpura.se)

### About Alzinova AB

*Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer's disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is currently under preclinical development, in preparation for human clinical trials. The Company further conducts development within diagnostics for the disease. Alzinova was founded by researchers from the MVAC research center at the University of Gothenburg, and by GU Ventures AB.*